Abstract
Long-acting im bromocriptine was administered to 7 patients with pituitary macroadenomas (4 acromegalics, 1 Nelson’s syndrome and 2 prolactinomas), with good tolerance except during the first 24 h. During a 42-day period hormonal, CT-scan and visual field variations were followed. In acromegalics HGH decrease was not evident, except in some isolated sample. In Nelson’s syndrome ACTH showed a 94% fall on day 14, even though a spontaneous oscillation cannot be ruled out, and recovery took place from day 21 on. PRL remained undetectable in both. In prolactinomas, PRL suffered a great decrease (91.8% and 96.3% on days 21 and 28 respectively) and remained well below its initial values up to the end of the study, in spite of partial recovery. In these 2 patients CT-scan evidenced shrinkage of tumor mass, which was not observed in the remaining 5 cases. Visual fields did not improve in the 2 cases initially affected (Nelson’s syndrome and 1 prolactinoma). Long-acting bromocriptine seems to have the same therapeutic uses of the oral form with the possible advantage of a better tolerance of full initial doses.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Thorner M.O., Besser G.M. Bromocriptine treatment of hyperprolactinaemic hypogonadism. Acta Endocrinol. (Kbh.) 88(Suppl. 216): 131, 1978.
Bergh T., Nillius S.J., Wide L. Bromocriptine treatment of 42 hyperprolactinemic women with secondary amenorrhoea. Acta Endocrinol. (Kbh.) 88: 435, 1978.
Bergh T., Nillius S.J., Wide L. Hyperprolactinemic amenorrhoea-Results of treatment with bromocriptine. Acta Endocrinol. (Kbh.) 88(Suppl. 216): 147, 1978.
Thorner M.O., Schran H.F., Evans W.S., Rogol A.D., Morris J.L., MacLeod R.M. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J. Clin. Endocrinol. Metab. 50: 1026, 1980.
Liuzzi A., Dallabonzana D., Oppizzi G., Verde G.G., Cozzi R., Chiodini P., Luccarelli G. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N. Engl. J. Med. 313: 656, 1985.
Molitch M.E., Elton R.L., Blackwell R.E., Caldwell B., Chang R.J., Jaffe R., Joplin G., Robbins R.J., Tyson J., Thorner M.O., Bromocriptine Study Group. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicentric study. J. Clin. Endocrinol. Metab. 60: 698, 1985.
Clayton R.N., Webb J., Heath D.A., Dunn P.J.S., Rolfe E.B., Hockley A.D. Dramatic and rapid shrinkage of a massive invasive prolactinoma with bromocriptine: A case report. Clin. Endocrinol. (Oxf.) 22: 573, 1985.
Bassetti M., Spada A., Pezzo G., Giannattasio G. Bromocriptine treatment reduces the cell size in human macroprolactinomas: A morphometric study. J. Clin. Endocrinol. Metab. 58: 268, 1984.
Belforte L., Camanni F., Chiodini G., Liuzzi A., Massara F., Molinatti G.M., Müller E.E., Silvestrini F. Long-term treatment with 2-Br-α-ergocryptine in acromegaly. Acta Endocrinol. (Kbh.) 85: 235, 1977.
Eskildsen P.C., Svendsen P.A., Vang L., Nerup J. Long-term treatment of acromegaly with bromocriptine. Acta Endocrinol. (Kbh.) 87: 687, 1978.
Kennedy A.L., Sheridan B., Montgomery D.A.D. ACTH and cortisol response to bromocriptine and results of long-term therapy in Cushing’s disease. Acta Endocrinol. (Kbh.) 89: 461, 1978.
Benker G., Hackenberg K., Hamburger B., Reinwein D. Effects of growth hormone release-inhibiting hormone and bromocriptine (CB 154) in states of abnormal pituitary-adrenal function. Clin. Endocrinol. (Oxf.) 5: 187, 1976.
Landolt A.M., Del Pozo E., Hayek J. Injectable bromocriptine to treat acute, oestrogen-induced swelling of invasive prolactinoma. Lancet 2: 111, 1981.
Gen M., Uozumi T., Ohta M., Ito A., Kajiwara H., Mori S. Necrotic changes in prolactinomas after long term administration of bromocriptine. J. Clin. Endocrinol. Metab. 59: 463, 1984.
Tucker H. StG., Grubb S.R., Wigand J.P., Taylon A., Lankford H.V., Blackard W., Becker D.P. Galactorrhea-amenorrhea syndrome: follow-up of forty-five patients after pituitary tumor removal. Ann. Intern. Med. 94: 302, 1981.
Serri O., Rasio E., Beauregard H., Hardy J., Somma M. Recurence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N. Engl. J. Med. 309: 280, 1983.
Nabarro J.D.N. Pituitary prolactinomas. Clin. Endocrinol. (Oxf.) 17: 129, 1982.
Del Pozo E., Schlüter K., Nüesch E., Rosenthaler J., Kerp L. Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormone. Eur. J. Clin. Pharmacol. 29: 615, 1986.
Grossman A., Ross R., Wass J.A.H., Besser G.M. Depot-bromocriptine treatment for prolactinomas and acromegaly. Clin. Endocrinol. (Oxf.) 24: 231, 1986.
Werner S., Hall K., Sjöberg H.E. Bromocriptine therapy in patients with acromegaly: effects on growth hormone, somatomedin A and prolactin. Acta Endocrinol. (Kbh.) 88: 199, 1978.
Clayton R.N., Vrionides Y., Lynch S.S., Butt W.R., London D.R. Response of acromegaly to long term bromocriptine therapy: a biochemical and clinical assessment. Acta Endocrinol. (Kbh.) 89: 469, 1978.
Wass J.A.H., Clemmons D.R., Underwood L.E., Barrow I., Besser G.M., Van Wyk J.J. Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly. Clin. Endocrinol.(Oxf) 17: 369, 1982.
Moses A.C., Molitch M.E., Sawin C.T., Jackson I., Biller B.J., Furlanetto R., Reichlin S. Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C. J. Clin. Endocrinol. Metab. 53: 753, 1981.
Lamberts S.W.J., Timmermans H.A.T., De Jong F.H., Birkenhäger J.C. The role of dopaminergic depletion in the pathogenesis of Cushing’s disease and the possible consequences for medical therapy. Clin. Endocrinol. (Oxf.) 7: 185, 1977.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Halperin, I., Rodriguez, M.D., Cardenal, C. et al. Treatment of pituitary macroadenomas secreting PRL, HGH or ACTH with long-acting bromocriptine. J Endocrinol Invest 10, 277–282 (1987). https://doi.org/10.1007/BF03348130
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348130